{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T04:29:03Z","timestamp":1793075343343,"version":"4.5.0"},"reference-count":127,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T00:00:00Z","timestamp":1621296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004338","name":"Universite Saint-Joseph","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004338","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"INSERM","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001674","name":"Leducq Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001674","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-16-RHUS-0007"],"award-info":[{"award-number":["ANR-16-RHUS-0007"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007175","name":"Conseil National de la Recherche Scientifique","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007175","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.atherosclerosis.2021.05.007","type":"journal-article","created":{"date-parts":[[2021,5,23]],"date-time":"2021-05-23T17:41:07Z","timestamp":1621791667000},"page":"11-22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":171,"special_numbering":"C","title":["APOE gene variants in primary dyslipidemia"],"prefix":"10.1016","volume":"328","author":[{"given":"Yara Abou","family":"Khalil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Rab\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0371-7539","authenticated-orcid":false,"given":"Catherine","family":"Boileau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Varret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib1","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.pathol.2018.11.002","article-title":"Apolipoprotein E in lipoprotein metabolism, health and cardiovascular disease","volume":"51","author":"Marais","year":"2019","journal-title":"Pathology"},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9010072","article-title":"Comparison of plasma lipoprotein composition and function in cerebral Amyloid Angiopathy and Alzheimer's disease","volume":"9","author":"Bonaterra-Pastra","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib3","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1161\/ATVBAHA.119.313877","article-title":"VLDL (Very-Low-Density lipoprotein)-apo E (apolipoprotein E) may influence lp(a) (lipoprotein [a]) synthesis or assembly","volume":"40","author":"Croyal","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib4","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/MOL.0000000000000146","article-title":"The crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemia","volume":"26","author":"Sacks","year":"2015","journal-title":"Curr. Opin. Lipidol."},{"issue":"Pt A","key":"10.1016\/j.atherosclerosis.2021.05.007_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.nbd.2014.08.025","article-title":"Structure and function in lipid metabolism, neurobiology, and Alzheimer's diseases","volume":"72","author":"Huang","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib6","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nrendo.2012.15","article-title":"The genetics of familial combined hyperlipidaemia","volume":"8","author":"Brouwers","year":"2012","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib7","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1161\/01.ATV.17.12.3542","article-title":"Lipoprotein heterogeneity and apolipoprotein B metabolism","volume":"17","author":"Packard","year":"1997","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib8","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.metabol.2006.04.009","article-title":"Differential effects of apolipoprotein E isoforms on lipolysis of very low-density lipoprotein triglycerides","volume":"55","author":"Hara","year":"2006","journal-title":"Metabolism"},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib9","doi-asserted-by":"crossref","first-page":"35711","DOI":"10.1074\/jbc.274.50.35711","article-title":"Apolipoprotein E participates in the regulation of very low density lipoprotein-triglyceride secretion by the liver","volume":"274","author":"Mensenkamp","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib10","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1093\/eurheartj\/ehz402","article-title":"Plasma levels of apolipoprotein E, APOE genotype, and all-cause and cause-specific mortality in 105\u2009949 individuals from a white general population cohort","volume":"40","author":"Rasmussen","year":"2019","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib11","unstructured":"Mahley RW, Rall JSC. Chapter 119: Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In: Scriver R, Beaudet AL, Sly WS, et al, editors 2001;Metabolic and Molecular Base of Inherited Disease:New York: McGraw-Hil. https:\/\/doi.org\/10.1036\/ommbid.148."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib12","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/aje\/155.6.487","article-title":"Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review","volume":"155","author":"Eichner","year":"2002","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib13","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1210\/jc.2015-3874","article-title":"The p.Leu167del Mutation in APOE Gene Causes Autosomal Dominant Hypercholesterolemia by Down-regulation of LDL Receptor Expression in Hepatocytes","volume":"101","author":"Cenarro","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"Suppl","key":"10.1016\/j.atherosclerosis.2021.05.007_bib14","doi-asserted-by":"crossref","first-page":"S183","DOI":"10.1194\/jlr.R800069-JLR200","article-title":"Structure determines function, from atherosclerosis to Alzheimer's disease to AIDS","volume":"50","author":"Mahley","year":"2009","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib15","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.dib.2016.01.060","article-title":"Data on plasma levels of apolipoprotein E, correlations with lipids and lipoproteins stratified by APOE genotype, and risk of ischemic heart disease","volume":"6","author":"Rasmussen","year":"2016","journal-title":"Data Brief"},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib16","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1194\/jlr.P083576","article-title":"Kinetics of plasma apolipoprotein E isoforms by LC-MS\/MS: a pilot study","volume":"59","author":"Blanchard","year":"2018","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib17","doi-asserted-by":"crossref","first-page":"17483","DOI":"10.1074\/jbc.273.28.17483","article-title":"Apolipoprotein E2 reduces the low density lipoprotein level in transgenic mice by impairing lipoprotein lipase-mediated lipolysis of triglyceride-rich lipoproteins","volume":"273","author":"Huang","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib18","first-page":"9","article-title":"The effect of apolipoprotein E polymorphism on serum metabolome - a population-based 10-year follow-up study","volume":"458","author":"Karjalainen","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib19","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1053\/meta.2001.21031","article-title":"Influence of remnant accumulation markers on plasma concentrations of two lipoprotein(a) subspecies (containing or free of apoE)","volume":"50","author":"Bach-Ngohou","year":"2001","journal-title":"Metabolism"},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib20","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1161\/ATVBAHA.116.308704","article-title":"Lipoprotein(a) mass levels increase significantly according to APOE genotype: an analysis of 431\u2009239 patients","volume":"37","author":"Moriarty","year":"2017","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib21","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.kint.2019.10.031","article-title":"Apolipoprotein E-related glomerular disorders","volume":"97","author":"Saito","year":"2020","journal-title":"Kidney Int."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib22","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/0005-2760(92)90257-V","article-title":"Apolipoprotein E1 Lys-146\u2013--Glu with type III hyperlipoproteinemia","volume":"1128","author":"Moriyama","year":"1992","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib23","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1172\/JCI118096","article-title":"Dominant expression of type III hyperlipoproteinemia. Pathophysiological insights derived from the structural and kinetic characteristics of ApoE-1 (Lys146-->Glu)","volume":"96","author":"Mann","year":"1995","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib24","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0022-2275(20)42076-0","article-title":"Two apolipoprotein E5 variants illustrate the importance of the position of additional positive charge on receptor-binding activity","volume":"32","author":"Wardell","year":"1991","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib25","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/S0022-2275(20)39106-9","article-title":"Apolipoprotein E5 (Glu212-->Lys): increased binding to cell surface proteoglycans but decreased uptake and lysosomal degradation in cultured fibroblasts","volume":"37","author":"Feussner","year":"1996","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib26","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/oxfordjournals.jbchem.a122618","article-title":"Identification of human apolipoprotein E variant gene: apolipoprotein E7 (Glu244,245\u2013--Lys244,245)","volume":"105","author":"Maeda","year":"1989","journal-title":"J. Biochem. (Tokyo)"},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib27","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1399-0004.1995.tb04063.x","article-title":"Population frequency of apolipoprotein E5 (Glu3-->Lys) and E7 (Glu244-->Lys, Glu245-->Lys) variants in western Japan","volume":"48","author":"Matsunaga","year":"1995","journal-title":"Clin. Genet."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib28","doi-asserted-by":"crossref","DOI":"10.1002\/mgg3.1281","article-title":"Clinical and genetic analysis of lipoprotein glomerulopathy patients caused by APOE mutations","volume":"8","author":"Yang","year":"2020","journal-title":"Mol Genet Genomic Med"},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib29","first-page":"4354","article-title":"Familial splenomegaly: macrophage hypercatabolism of lipoproteins associated with apolipoprotein E mutation [apolipoprotein E (\u0394149 leu)]","volume":"85","author":"Nguyen","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"12","key":"10.1016\/j.atherosclerosis.2021.05.007_bib30","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1002\/alz.12165","article-title":"APOE and dementia - resequencing and genotyping in 105,597 individuals","volume":"16","author":"Rasmussen","year":"2020","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib31","first-page":"276","article-title":"Fat transport in lipoproteins\u2013an integrated approach to mechanisms and disorders","author":"Fredrickson","year":"1967","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib32","first-page":"891","article-title":"Classification of hyperlipidaemias and hyperlipoproteinaemias","volume":"43","author":"Beaumont","year":"1970","journal-title":"Bull. World Health Organ."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib33","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.jacl.2016.09.009","article-title":"Familial defective apolipoprotein B-100: a review","volume":"10","author":"Andersen","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib34","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1016\/j.jacc.2020.03.057","article-title":"Worldwide prevalence of familial hypercholesterolemia: meta-analyses of 11 million subjects","volume":"75","author":"Beheshti","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib35","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1161\/CIRCULATIONAHA.119.044795","article-title":"Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis","volume":"141","author":"Hu","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib36","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1210\/jc.2012-1563","article-title":"Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication","volume":"97","author":"Benn","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib37","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1172\/JCI107332","article-title":"Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia","volume":"52","author":"Goldstein","year":"1973","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib38","doi-asserted-by":"crossref","first-page":"6919","DOI":"10.1073\/pnas.84.19.6919","article-title":"Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding","volume":"84","author":"Innerarity","year":"1987","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib39","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1073\/pnas.86.2.587","article-title":"Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100","volume":"86","author":"Soria","year":"1989","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib40","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat. Genet."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib41","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.pathol.2018.10.012","article-title":"PCSK9: from biology to clinical applications","volume":"51","author":"Blanchard","year":"2019","journal-title":"Pathology"},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib42","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1124\/pr.116.012989","article-title":"The proprotein convertases in hypercholesterolemia and cardiovascular diseases: emphasis on proprotein convertase subtilisin\/kexin 9","volume":"69","author":"Seidah","year":"2017","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib43","doi-asserted-by":"crossref","first-page":"E1811","DOI":"10.1002\/humu.21348","article-title":"Molecular spectrum of autosomal dominant hypercholesterolemia in France","volume":"31","author":"Marduel","year":"2010","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib44","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1038\/ejhg.2010.94","article-title":"A fourth locus for autosomal dominant hypercholesterolemia maps at 16q22.1","volume":"18","author":"Marques-Pinheiro","year":"2010","journal-title":"Eur J Hum Genet EJHG"},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib45","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1399-0004.2010.01485.x","article-title":"A presumptive new locus for autosomal dominant hypercholesterolemia mapping to 8q24.22","volume":"79","author":"Cenarro","year":"2011","journal-title":"Clin. Genet."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib46","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/humu.22215","article-title":"Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation","volume":"34","author":"Marduel","year":"2013","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib47","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.atherosclerosis.2013.09.007","article-title":"APOE p.Leu167del mutation in familial hypercholesterolemia","volume":"231","author":"Awan","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib48","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1194\/jlr.P055699","article-title":"Global molecular analysis and APOE mutations in a cohort of autosomal dominant hypercholesterolemia patients in France","volume":"57","author":"Wintjens","year":"2016","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib49","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1161\/CIRCRESAHA.115.304660","article-title":"Mutations in STAP1 are associated with autosomal dominant hypercholesterolemia","volume":"115","author":"Fouchier","year":"2014","journal-title":"Circ. Res."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib50","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1161\/ATVBAHA.119.313470","article-title":"Taking one step back in familial hypercholesterolemia: STAP1 does not alter plasma LDL (Low-Density lipoprotein) cholesterol in mice and humans","volume":"40","author":"Loaiza","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib51","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.atherosclerosis.2019.11.025","article-title":"Predicted pathogenic mutations in STAP1 are not associated with clinically defined familial hypercholesterolemia","volume":"292","author":"Lamiquiz-Moneo","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib52","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1172\/JCI111532","article-title":"New mutants of apolipoprotein E associated with atherosclerotic diseases but not to type III hyperlipoproteinemia","volume":"74","author":"Yamamura","year":"1984","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib53","first-page":"283","article-title":"Association of the apolipoprotein E4 allele with hypercholesterolemia in apparently healthy male adults in Tokyo","volume":"32","author":"Tsuchiya","year":"1987","journal-title":"Jinrui Idengaku Zasshi Jpn J Hum Genet"},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib54","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/elps.11501401164","article-title":"Characterization of the gene for apolipoprotein E5-Frankfurt (Gln81->Lys, Cys112->Arg) by polymerase chain reaction, restriction isotyping, and temperature gradient gel electrophoresis","volume":"14","author":"Ruzicka","year":"1993","journal-title":"Electrophoresis"},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib55","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0021-9150(90)90041-G","article-title":"Frequency and role of apo E phenotype in familial hypercholesterolemia and non-familial hyperlipidemia in the Japanese","volume":"82","author":"Kitahara","year":"1990","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib56","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0021-9150(96)06068-6","article-title":"Increased serum remnant lipoproteins in patients with apolipoprotein E7 (apo E Suita)","volume":"131","author":"Yanagi","year":"1997","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib57","first-page":"937","article-title":"Characterization of five new mutants in the carboxyl-terminal domain of human apolipoprotein E: no cosegregation with severe hyperlipidemia","volume":"52","author":"van den Maagdenberg","year":"1993","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib58","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/sj.ejhg.5201480","article-title":"Variable expressivity of the clinical and biochemical phenotype associated with the apolipoprotein E p.Leu149del mutation","volume":"13","author":"Faivre","year":"2005","journal-title":"Eur J Hum Genet EJHG"},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib59","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.atherosclerosis.2012.03.011","article-title":"Apolipoprotein E gene mutations in subjects with mixed hyperlipidemia and a clinical diagnosis of familial combined hyperlipidemia","volume":"222","author":"Solanas-Barca","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib60","doi-asserted-by":"crossref","first-page":"12931","DOI":"10.1074\/jbc.M113.538124","article-title":"Molecular basis for increased risk for late-onset Alzheimer disease due to the naturally occurring L28P mutation in apolipoprotein E4","volume":"289","author":"Argyri","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib61","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ymgme.2006.02.015","article-title":"Structural and phylogenetic approaches to assess the significance of human Apolipoprotein E variation","volume":"89","author":"Corbo","year":"2006","journal-title":"Mol. Genet. Metabol."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib62","first-page":"224","article-title":"Familial combined hyperlipidemia: current knowledge, perspectives, and controversies","volume":"70","author":"Bello-Chavolla","year":"2018","journal-title":"Rev Investig Clin Organo Hosp Enfermedades Nutr"},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib63","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1172\/JCI113096","article-title":"Apolipoprotein E2-Christchurch (136 Arg\u2013--Ser). New variant of human apolipoprotein E in a patient with type III hyperlipoproteinemia","volume":"80","author":"Wardell","year":"1987","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib64","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/S0022-2275(20)39106-9","article-title":"Apolipoprotein E5 (Glu212-->Lys): increased binding to cell surface proteoglycans but decreased uptake and lysosomal degradation in cultured fibroblasts","volume":"37","author":"Feussner","year":"1996","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib65","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0005-2760(96)00014-8","article-title":"Characterization of a novel variant of apolipoprotein E, E2 Fukuoka (Arg-224--> Gln) in a hyperlipidemic patient with xanthomatosis","volume":"1301","author":"Moriyama","year":"1996","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib66","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1172\/JCI111085","article-title":"Identification of a new structural variant of human apolipoprotein E, E2(Lys146 leads to Gln), in a type III hyperlipoproteinemic subject with the E3\/2 phenotype","volume":"72","author":"Rall","year":"1983","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib67","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/BF00291607","article-title":"Apolipoprotein E3-Leiden. A new variant of human apolipoprotein E associated with familial type III hyperlipoproteinemia","volume":"73","author":"Havekes","year":"1986","journal-title":"Hum. Genet."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib68","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0021-9150(95)06745-0","article-title":"Incomplete dominance of type III hyperlipoproteinemia is associated with the rare apolipoprotein E2 (Arg136-->Ser) variant in multigenerational pedigree studies","volume":"122","author":"Pocovi","year":"1996","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib69","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0021-9150(96)05969-2","article-title":"Apo E variants in patients with type III hyperlipoproteinemia","volume":"127","author":"Civeira","year":"1996","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib70","first-page":"15","article-title":"Frequency of rare mutations and common genetic variations in severe hypertriglyceridemia in the general population of Spain","volume":"82","author":"Lamiquiz-Moneo","year":"2016","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib71","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1172\/JCI113988","article-title":"Type III hyperlipoproteinemia associated with apolipoprotein E phenotype E3\/3. Structure and genetics of an apolipoprotein E3 variant","volume":"83","author":"Rall","year":"1989","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib72","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0021-9258(18)46040-1","article-title":"The functional characteristics of a human apolipoprotein E variant (cysteine at residue 142) may explain its association with dominant expression of type III hyperlipoproteinemia","volume":"267","author":"Horie","year":"1992","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib73","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0005-2760(89)90043-X","article-title":"Apolipoprotein E-1Harrisburg: a new variant of apolipoprotein E dominantly associated with type III hyperlipoproteinemia","volume":"1005","author":"Mann","year":"1989","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib74","first-page":"67","article-title":"Variable phenotypic expression of nonsense mutation p.Thr5* in the APOE gene","volume":"9","author":"Leren","year":"2016","journal-title":"Mol Genet Metab Rep"},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib75","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1161\/01.ATV.17.5.865","article-title":"The apolipoprotein E2 (Arg145Cys) mutation causes autosomal dominant type III hyperlipoproteinemia with incomplete penetrance","volume":"17","author":"de Villiers","year":"1997","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib76","first-page":"281","article-title":"10-bp deletion in the apolipoprotein epsilon gene causing apolipoprotein E deficiency and severe type III hyperlipoproteinemia","volume":"58","author":"Feussner","year":"1996","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib77","first-page":"381","article-title":"A novel apolipoprotein E mutation, ApoE Tsukuba (Arg 114 Cys), in lipoprotein glomerulopathy","volume":"23","author":"Hagiwara","year":"2008","journal-title":"Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc"},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib78","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s13730-019-00380-w","article-title":"A case of apolipoprotein E Toyonaka and homozygous apolipoprotein E2\/2 showing non-immune membranous nephropathy-like glomerular lesions with foamy changes","volume":"8","author":"Kato","year":"2019","journal-title":"CEN Case Rep"},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib79","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1046\/j.1523-1755.1999.00572.x","article-title":"A novel apolipoprotein E mutation, E2 (Arg25Cys), in lipoprotein glomerulopathy","volume":"56","author":"Matsunaga","year":"1999","journal-title":"Kidney Int."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib80","first-page":"14","article-title":"A novel apolipoprotein E mutation caused by a five amino acid deletion in a Chinese family with lipoprotein glomerulopathy: a case report","volume":"41","author":"Xie","year":"2019","journal-title":"Diagn. Pathol."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib81","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/CM9.0000000000000050","article-title":"A novel apolipoprotein E mutation (p.Arg150Cys) in a Chinese patient with lipoprotein glomerulopathy","volume":"132","author":"Ku","year":"2019","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib82","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1159\/000111828","article-title":"Identification of apolipoprotein E Guangzhou (arginine 150 proline), a new variant associated with lipoprotein glomerulopathy","volume":"28","author":"Luo","year":"2008","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib83","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.jacc.2008.06.050","article-title":"Frequency of low-density lipoprotein receptor gene mutations in patients with a clinical diagnosis of familial combined hyperlipidemia in a clinical setting","volume":"52","author":"Civeira","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib84","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0888-7543(88)90130-9","article-title":"Genotyping and sequence analysis of apolipoprotein E isoforms","volume":"3","author":"Emi","year":"1988","journal-title":"Genomics"},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib85","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0021-9150(03)00194-1","article-title":"Disappearance of intraglomerular lipoprotein thrombi and marked improvement of nephrotic syndrome by bezafibrate treatment in a patient with lipoprotein glomerulopathy","volume":"169","author":"Arai","year":"2003","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib86","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/ki.2013.335","article-title":"Hereditary features, treatment, and prognosis of the lipoprotein glomerulopathy in patients with the APOE Kyoto mutation","volume":"85","author":"Hu","year":"2014","journal-title":"Kidney Int."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib87","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0022-2275(20)42048-6","article-title":"Characterization of a new apolipoprotein E5 variant detected in two French-Canadian subjects","volume":"32","author":"Mailly","year":"1991","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib88","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1681\/ASN.V1071590","article-title":"Apolipoprotein E2\/E5 variants in lipoprotein glomerulopathy recurred in transplanted kidney","volume":"10","author":"Miyata","year":"1999","journal-title":"J Am Soc Nephrol JASN"},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib89","doi-asserted-by":"crossref","first-page":"13642","DOI":"10.1016\/S0021-9258(18)42261-2","article-title":"Heterozygosity for apolipoprotein E-4Philadelphia(Glu13\u2013--Lys, Arg145\u2013--Cys) is associated with incomplete dominance of type III hyperlipoproteinemia","volume":"267","author":"Lohse","year":"1992","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib90","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/(SICI)1098-1004(1998)11:6<417::AID-HUMU1>3.0.CO;2-5","article-title":"Molecular basis of type III hyperlipoproteinemia in Germany","volume":"11","author":"Feussner","year":"1998","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib91","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMc072088","article-title":"APOE Kyoto mutation in European Americans with lipoprotein glomerulopathy","volume":"357","author":"Rovin","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib92","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1365-2362.1992.tb01511.x","article-title":"Severe type III hyperlipoproteinemia associated with unusual apolipoprotein E1 phenotype and epsilon 1\/\u2019null\u2019 genotype","volume":"22","author":"Feussner","year":"1992","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib93","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1258\/0004563054255498","article-title":"Discovery and consequences of apolipoprotein-epsilon(3Groningen): a G-insertion in codon 95\/96 that is predicted to cause a premature stop codon","volume":"42","author":"Dijck-Brouwer","year":"2005","journal-title":"Ann. Clin. Biochem."},{"issue":"93","key":"10.1016\/j.atherosclerosis.2021.05.007_bib94","first-page":"89","article-title":"Compound heterozygote for both rare apolipoprotein E1 (Gly127-->Asp, Arg158-->Cys) and E3(Cys112-->Arg, Arg251-->Gly) alleles in a multigeneration pedigree with hyperlipoproteinaemia","volume":"1997","author":"Richard","year":"1979","journal-title":"Clin Sci Lond Engl"},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib95","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s100380170014","article-title":"A novel apolipoprotein E5 variant with a 24-bp insertion causing hyperlipidemia","volume":"46","author":"Yamanouchi","year":"2001","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib96","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1046\/j.1365-2362.1996.83232.x","article-title":"Apolipoprotein E2 (Arg-136-->Cys), a variant of apolipoprotein E associated with late-onset dominance of type III hyperlipoproteinaemia","volume":"26","author":"Feussner","year":"1996","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib97","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0022-2275(20)39754-6","article-title":"Identification and characterization of a novel apolipoprotein E variant, apolipoprotein E3\u2019 (Arg136-->His): association with mild dyslipidemia and double pre-beta very low density lipoproteins","volume":"36","author":"Minnich","year":"1995","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib98","first-page":"699","article-title":"Detection of a new apolipoprotein-E mutation in type III hyperlipidemia using deoxyribonucleic acid restriction isotyping","volume":"78","author":"Walden","year":"1994","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib99","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0939-4753(03)80024-8","article-title":"Two Italian kindreds carrying the Arg136-->Ser mutation of the Apo E gene: development of premature and severe atherosclerosis in the presence of epsilon 2 as second allele","volume":"13","author":"Rolleri","year":"2003","journal-title":"Nutr Metab Cardiovasc Dis NMCD"},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib100","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1159\/000045513","article-title":"Association of a novel 3-amino acid deletion mutation of apolipoprotein E (Apo E Tokyo) with lipoprotein glomerulopathy","volume":"83","author":"Konishi","year":"1999","journal-title":"Nephron"},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib101","doi-asserted-by":"crossref","first-page":"131","DOI":"10.5551\/jat.11.131","article-title":"Mutations in Japanese subjects with primary hyperlipidemia\u2013results from the Research committee of the ministry of health and welfare of Japan since 1996\u2013","volume":"11","author":"Maruyama","year":"2004","journal-title":"J. Atherosclerosis Thromb."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib102","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0021-9150(94)05393-W","article-title":"Identification of a new apolipoprotein E variant (E2 Arg142-->Leu) in type III hyperlipidemia","volume":"112","author":"Richard","year":"1995","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib103","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s004670050032","article-title":"A new variant of apolipoprotein E (apo E Maebashi) in lipoprotein glomerulopathy","volume":"14","author":"Ogawa","year":"2000","journal-title":"Pediatr Nephrol Berl Ger"},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib104","first-page":"163","article-title":"Characterization of an apolipoprotein E3 variant (Arg 145-->His) associated with mild hypertriglyceridemia","volume":"31","author":"Hidaka","year":"2001","journal-title":"Ann. Clin. Lab. Sci."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib105","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1681\/ASN.V85820","article-title":"Apolipoprotein E Sendai (arginine 145-->proline): a new variant associated with lipoprotein glomerulopathy","volume":"8","author":"Oikawa","year":"1997","journal-title":"J Am Soc Nephrol JASN"},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib106","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s13730-018-0309-2","article-title":"A case of lipoprotein glomerulopathy with a rare apolipoprotein E isoform combined with neurofibromatosis type I","volume":"7","author":"Takasaki","year":"2018","journal-title":"CEN Case Rep"},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib107","first-page":"278","article-title":"APOE1 mutation in a patient with type III hyperlipoproteinaemia: detailed genetic analysis required","volume":"70","author":"Visser","year":"2012","journal-title":"Neth. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib108","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0022-2275(20)42759-2","article-title":"Genetic heterogeneity in familial dysbetalipoproteinemia. The E2(lys146\u2013--gln) variant results in a dominant mode of inheritance","volume":"31","author":"Smit","year":"1990","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib109","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0021-9150(96)05819-4","article-title":"Apolipoprotein E1-Hammersmith (Lys146-->Asn;Arg147-->Trp), due to a dinucleotide substitution, is associated with early manifestation of dominant type III hyperlipoproteinaemia","volume":"124","author":"Hoffer","year":"1996","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib110","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1053\/j.ajkd.2005.12.031","article-title":"Lipoprotein glomerulopathy: a new apolipoprotein E mutation with enhanced glomerular binding","volume":"47","author":"Sam","year":"2006","journal-title":"Am J Kidney Dis Off J Natl Kidney Found"},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib111","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1159\/000478902","article-title":"A case of lipoprotein glomerulopathy with apoE chicago and apoE (Glu3Lys) treated with fenofibrate","volume":"7","author":"Kodera","year":"2017","journal-title":"Case Rep Nephrol Dial"},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib112","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.transproceed.2010.03.104","article-title":"Novel genetic mutation in apolipoprotein E2 homozygosis and its implication in organ donation: a case report","volume":"42","author":"Cautero","year":"2010","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib113","first-page":"3442","article-title":"A new apolipoprotein E mutation, apoE Las Vegas, in a European-American with lipoprotein glomerulopathy","volume":"25","author":"Bomback","year":"2010","journal-title":"Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc"},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib114","first-page":"751","article-title":"A novel variant apolipoprotein E Okayama in a patient with lipoprotein glomerulopathy","volume":"23","author":"Kinomura","year":"2008","journal-title":"Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc"},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib115","doi-asserted-by":"crossref","first-page":"733","DOI":"10.5551\/jat.41996","article-title":"The novel apolipoprotein E mutation ApoE chengdu (c.518T\uff1eC, p.L173P) in a Chinese patient with lipoprotein glomerulopathy","volume":"25","author":"Wu","year":"2018","journal-title":"J. Atherosclerosis Thromb."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib116","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1046\/j.1523-1755.1999.00677.x","article-title":"A novel 18-amino acid deletion in apolipoprotein E associated with lipoprotein glomerulopathy","volume":"56","author":"Ando","year":"1999","journal-title":"Kidney Int."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib117","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.1073\/pnas.79.15.4696","article-title":"Structural basis for receptor binding heterogeneity of apolipoprotein E from type III hyperlipoproteinemic subjects","volume":"79","author":"Rall","year":"1982","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib118","doi-asserted-by":"crossref","first-page":"542","DOI":"10.5551\/jat.10165","article-title":"Significance of a novel apolipoprotein E variant, ApoE Osaka\/Kurashiki, in lipoprotein glomerulopathy","volume":"18","author":"Saito","year":"2011","journal-title":"J. Atherosclerosis Thromb."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib119","first-page":"166","article-title":"[Discovery of a Chinese Tibetan patient with lipoprotein glomerulopathy due to APOE Osaka\/Kurashiki variant]","volume":"37","author":"Yang","year":"2020","journal-title":"Zhonghua Yi Xue Yi Chuan Xue Za Zhi Zhonghua Yixue Yichuanxue Zazhi Chin J Med Genet"},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib120","doi-asserted-by":"crossref","first-page":"531","DOI":"10.5551\/jat.7377","article-title":"A novel apolipoprotein E mutation, ApoE Osaka (Arg158 Pro), in a dyslipidemic patient with lipoprotein glomerulopathy","volume":"18","author":"Mitani","year":"2011","journal-title":"J. Atherosclerosis Thromb."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib121","doi-asserted-by":"crossref","first-page":"536","DOI":"10.5551\/jat.8102","article-title":"A novel mutation ApoE2 Kurashiki (R158P) in a patient with lipoprotein glomerulopathy","volume":"18","author":"Tokura","year":"2011","journal-title":"J. Atherosclerosis Thromb."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib122","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0009-8981(00)00372-7","article-title":"Apolipoprotein E1 Baden (Arg(180)-->Cys). A new apolipoprotein E variant associated with hypertriglyceridemia","volume":"303","author":"Hoffmann","year":"2001","journal-title":"Clin Chim Acta Int J Clin Chem"},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib123","first-page":"187","article-title":"A novel apolipoprotein E2 variant, E2Toranomon (Q187E), identified in a type III hyperlipoproteinemia patient with coronary atherosclerosis","volume":"140","author":"Okubo","year":"1998","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib124","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000487919","article-title":"Membranous nephropathy-like apolipoprotein E deposition disease with apolipoprotein E Toyonaka (Ser197Cys) and a homozygous apolipoprotein E2\/2","volume":"8","author":"Fukunaga","year":"2018","journal-title":"Case Rep Nephrol Dial"},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib125","doi-asserted-by":"crossref","first-page":"45","DOI":"10.5414\/CNCS109509","article-title":"A case of nephrotic syndrome showing contemporary presence of apolipoprotein E2 homozygote glomerulopathy and membranous nephropathy-like findings modified by apolipoprotein E Toyonaka","volume":"6","author":"Hirashima","year":"2018","journal-title":"Clin Nephrol Case Stud"},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib126","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/S0022-2275(20)41380-X","article-title":"Familial apolipoprotein E deficiency and type III hyperlipoproteinemia due to a premature stop codon in the apolipoprotein E gene","volume":"33","author":"Lohse","year":"1992","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2021.05.007_bib127","first-page":"57","article-title":"A rare cause of nephrotic syndrome: lipoprotein glomerulopathy","volume":"15","author":"Cheung","year":"2009","journal-title":"Hong Kong Med J Xianggang Yi Xue Za Zhi"}],"updated-by":[{"DOI":"10.1016\/j.atherosclerosis.2023.117366","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000}}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002191502100232X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002191502100232X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T02:20:18Z","timestamp":1777429218000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002191502100232X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":127,"alternative-id":["S002191502100232X"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2021.05.007","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"APOE gene variants in primary dyslipidemia","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2021.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}